The Hidden Environmental Toll: New Links Between Industrial Pollution and Progressive Supranuclear Palsy on October 28, 2026October 29, 2026 Posted by Nila Kartika Wati
The Hidden Heart Risk: How Nighttime Light Pollution Is Quietly Remodeling Our Cardiovascular Health on October 28, 2026 Posted by
The AI Revolution: Navigating Your Career in the Age of Intelligent Automation on October 28, 2026 Posted by
The Metabolic Paradox: Turning a Cancer’s Ally into an Immune System Weapon on October 28, 2026 Posted by
Pioneering Wellness: Dr. Angela Neal-Barnett’s Decades-Long Fight Against Anxiety in the Black Community on October 28, 2026 Posted by
Beyond the Label: New Research Reveals How Sweeteners and Medications Reshape the Gut Microbiome on October 28, 2026 Posted by
The Hidden Environmental Toll: New Links Between Industrial Pollution and Progressive Supranuclear Palsy on October 28, 2026October 29, 2026 Posted by Nila Kartika Wati
The Hidden Heart Risk: How Nighttime Light Pollution Is Quietly Remodeling Our Cardiovascular Health on October 28, 2026 Posted by
The AI Revolution: Navigating Your Career in the Age of Intelligent Automation on October 28, 2026 Posted by
Posted in Sleep Health Advancing Neuroscience: Alkermes Opens 9th Annual Pathways Research Awards with Expanded Focus on Sleep Medicine on September 23, 2026
Posted in Medical Innovations Pharma Pulse: Novo Nordisk’s Consumer-Centric Pivot and Alkermes’ ADHD Breakthrough on September 21, 2026
Posted in Digital Health Tools Beyond Narcolepsy: Alkermes Unveils Potential ADHD Breakthrough with Orexin Agonists on September 21, 2026
Posted in Sleep Health New Horizons in Narcolepsy Treatment: Alkermes Reports Sustained Efficacy for Alixorexton in Long-Term Extension Study on August 10, 2026
Posted in Sleep Health New Horizons in Narcolepsy Treatment: Alkermes Reports Sustained Efficacy for Alixorexton in Long-Term Study on August 2, 2026
Posted in Sleep Health Breakthrough in Narcolepsy Treatment: Alkermes’ Alixorexton Shows Sustained Efficacy in Long-Term Clinical Study on July 25, 2026
Posted in Medical Innovations The Orexin Frontier: How Alkermes Is Positioning Its "Alixorexton" to Disrupt the Sleep Medicine Landscape on June 27, 2026
Posted in Sleep Health Advancing Sleep Medicine: Alkermes Secures Key Orphan Drug Designations for Alixorexton in Narcolepsy and Idiopathic Hypersomnia on June 17, 2026
Posted in Sleep Health Breakthrough in Sleep Medicine: Alkermes’ LUMRYZ Shows Promise for Idiopathic Hypersomnia in Phase 3 Trial on June 2, 2026 rifanmuazin
Posted in Sleep Health Breakthrough in Sleep Medicine: Alkermes’ LUMRYZ Shows Promise for Idiopathic Hypersomnia in Phase 3 Study on May 22, 2026 rifanmuazin
